In conclusion, this study suggests that EGFR mutations were more likely to occur in non‐smoking, stage III–IV, and female patients with lung adenocarcinoma, whereas ALK&ROS1 gene rearrangements were more likely to occur in young patients with lung adenocarcinoma. This evidence concerns the gene ROS1 and lung adenocarcinoma.